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Abstract
The rodent Pig-a assay is a flow cytometric, phenotype-based method used to mea-
sure in vivo somatic cell mutation. An Organization for Economic Co-operation and
Development (OECD) test guideline is currently being developed to support routine
use of the assay for regulatory purposes (OECD project number 4.93). This article
provides advice on best practices for designing and conducting rodent Pig-a studies
in support of evaluating test substance safety, with a focus on the rat model. Various
aspects of assay conduct, including laboratory proficiency, minimum number of ani-
mals per dose group, preferred treatment and blood sampling schedule, and statistical
analysis are described.
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1 | INTRODUCTION
The phosphatidylinositol glycan, class A (Pig-a) gene codes for an
enzyme that is essential for glycosylphosphatidylinositol (GPI) anchor
biosynthesis (Miyata et al., 1993). Thus, inactivating Pig-a mutations
result in cells that lack cell surface GPI anchors, and as a consequence,
GPI-anchored protein(s); this phenotype represents a reliable reporter
of Pig-a mutation in vivo (Kimoto et al., 2011b; Revollo et al., 2018,
2019, 2020; Dad et al., 2020). The analytical approach used to per-
form these assays utilizes fluorescently conjugated antibodies against
GPI-anchored cell surface epitopes, which makes it possible to mea-
sure mutant cell frequencies via flow cytometry (reviewed by
Gollapudi et al., 2015).
Rodent studies have focused on measuring mutations using
erythrocytes, as these cells are easily obtained in sufficient quantity
via small volume blood draws. The low blood volume requirement,
option for multiple blood draws without euthanizing animals, compati-
bility with commonly used rodent models, and relatively low cost of
these studies in comparison to other in vivo mutation test systems, all
make the Pig-a assay attractive for studies of somatic cell mutations
(Schuler et al., 2011; Gollapudi et al., 2015).
The erythrocyte-based Pig-a assay is considered useful for regula-
tory safety assessments. For example, as described by the International
Council for Harmonization of Technical Requirements for Pharmaceuti-
cals for Human Use (ICH) M7(R1) Guideline on the Assessment and
Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals
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(ICH, 2017), the rodent Pig-a assay is one of the recommended follow-
up tests to a positive bacterial mutagenicity finding. This and other use
cases have led to efforts to develop an Organization for Economic
Cooperation and Development (OECD) test guideline to support regula-
tory safety assessment studies (OECD project number 4.93).
Several laboratories are establishing proficiency with the assay
ahead of test guideline acceptance, and in some cases conduct rodent
Pig-a studies in order to generate supplemental information for regu-
latory approval packages. We have therefore developed these recom-
mendations with the goal of providing stakeholders with current
thinking and best-practices advice regarding laboratory training, study
design, and implementation of rodent Pig-a studies. The minimum
number of animals per dose group, a preferred treatment and blood
harvest schedule, statistical analysis, and other considerations are
described. More detailed information on the analytical procedures
involved with conducting the assays can be found elsewhere (Kimoto
et al., 2011a; Dertinger et al., 2011b; Bemis et al., 2019; Chikura
et al., 2019; Dobrovolsky et al., 2020; Chikura et al., 2021). The advice
provided herein has been designed to serve the needs of the genetic
toxicology community as they contemplate establishing laboratory
proficiency and/or conducting these studies.
2 | IN-LIFE AND ANALYTICAL SITE
CONSIDERATIONS
2.1 | In-life facility
The in-life portion of the test should be conducted at a site where
work is overseen by an Institutional Animal Care and Use Committee
(IACUC), an Animal Welfare and Ethical Review Body (AWERB), or a
local equivalent. This oversight ensures that experiments utilizing ver-
tebrate animals have merit, animal welfare standards are met, staff
have been trained on all necessary procedures, and all aspects of the
work are sufficiently supervised.
Standard housing, bedding, enrichment, feed and water schedules
should be employed, and animals should be group housed unless
exceptions are scientifically justified (e.g., aggression, or endpoint spe-
cific requirements when the Pig-a assay is integrated into a repeat-
dose general toxicology study). As discussed in more detail below,
some studies may involve only one sex, while other studies are con-
ducted with both sexes.
One of the major advantages of the Pig-a gene mutation assay is
that it can be performed with transgenic animals as well as more widely
available, non-transgenic laboratory rodent models (Shemansky
et al., 2019). This facilitates the use of the most appropriate species/
strain when evaluating mutagenicity in vivo, a decision that may be
influenced by pharmacodynamic, pharmacokinetic, tolerability, or
bioanalytical data. While this flexibility is clearly beneficial, it is impor-
tant for the in-life facility to have prior experience with each specific
rodent strain being contemplated for a definitive study. As explained
below, this is because each regulatory study should have an accompa-
nying historical negative control database for the animal model used.
The majority of rodent Pig-a experiments conducted for regulatory
safety assessment are expected to involve either stand-alone or inte-
grated study designs that consist of 28-consecutive days of dosing.
Laboratories, therefore, should have adequate staff to ensure the dos-
ing schedule is maintained without interruption, and that the health of
animals is monitored regularly. Veterinary staff and the Study Director/
Principal Investigator must be present physically or available on-call
throughout the duration of the in-life phase in case prompt decisions
about treatment (e.g., dose suspension, discontinuation, or adjustment)
need to be made due to unexpected morbidity or mortality.
In many cases, red blood cell labeling and flow cytometric ana-
lyses are conducted at the same facility that conducts the in-life phase
of the study. However, we have separated the in-life phase from the
flow cytometric analysis phase to emphasize that these functions can
be performed at different facilities. Briefly, as described in greater
detail below, anti-coagulated blood samples that are kept cold
( 4C), not frozen, throughout transportation are compatible with
analysis. Furthermore, procedures for freezing blood samples have
been described (Avlasevich et al., 2019), and these can be used for
shipping frozen samples to a separate analytical facility, provided sam-
ples remain frozen throughout transportation.
2.2 | Analytical facility
Each facility analyzing the blood samples should be able to provide
assurance that proficiency demonstrations have been successfully
completed and that historical negative control databases have been
generated for the animal model being considered for a regulatory
safety assessment study. It is important for the staff to have demon-
strated proficiency with sample processing and analysis. Based on the
authors' collective experience with training numerous personnel
across different laboratories, we recommend a three-step process.
After personnel have been introduced to the necessary blood
sample processing and flow cytometric analysis procedures, the first
key set of recommended proficiency experiments are reconstruction
or “spiking” experiments (for details, see Raschke et al., 2016). Briefly,
a single rodent is exposed to a known, potent mutagenic substance,
for example, N-ethyl-N-nitrosourea (ENU). After an appropriate pheno-
typic expression time that allows elevated mutant reticulocyte (MUT
RET) and mutant erythrocyte (MUT RBC) frequencies to appear in the
peripheral blood compartment, blood from the exposed rodent and a
sex/age-matched negative control animal (either naïve or vehicle
treated) should be collected. (Note: hereafter, “MUT RET/RBC” is
used to indicate both MUT RET and MUT RBC.) The two blood sam-
ples are combined in a series of serial dilutions to create a range of
MUT RET/RBC frequencies (i.e., spiked samples). After determining
MUT RET/RBC frequencies separately for the mutagen-treated and
the negative control animal, expected intermediate frequencies can
be calculated for the spiked samples based on the proportion of blood
from the mutagen-exposed animal added to the negative control
blood. By conducting reconstruction experiments on several separate
occasions, and with several replicates per spiked sample, staff can be
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trained on important elements of the assay by using a minimal number
of animals. The proficiency of staff members is established by demon-
strating agreement between the observed and expected MUT RET/
RBC frequencies (Raschke et al., 2016). Successful completion of
spiking experiments represents a useful, 3Rs-friendly gateway to fur-
ther proficiency investigations as described below.
The second step requires the laboratory to reproduce expected
results from high quality, peer-reviewed data (as collected in the on-
F IGURE 1 Reticulocyte (RET), and mutant reticulocyte (MUT RET) and mutant erythrocyte (MUT RBC) frequencies are graphed for male and
female rats (39 each) that had been exposed to one of several common vehicles. Blood samples were collected when the rats were 7 weeks old.
Whereas each circle represents an individual animal, the ranges are denoted by the length of horizonal lines, and group means are indicated by a
vertical tick mark. These data were evaluated by Restricted Maximum Likelihood analysis and demonstrate that variation in %RET is dominated
by sex (75%, with males > females). On the other hand, MUT RET and MUT RBC variation is mainly attributable to inter-animal variation (72–
91%), with much lower contributions from sex (2–8%) and study number (8–21%)
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line Pig-a database described in Shemansky et al., 2019). This should
be demonstrated for MUT RET/RBC frequencies using a minimum of
two well-established mutagenic substances. These experiments
should use doses that give reproducible and dose-related increases in
mutant frequencies and demonstrate the sensitivity and dynamic
range of the test system. Mutagenic agents that have been studied at
multiple laboratories for this purpose include, but are not limited to:
ENU, 7,12-dimethylbez[a]anthracene (DMBA), 4-nitroquinoline
1-oxide (4-NQO), melphalan, thiotepa, 1,3-propane sultone, procarba-
zine, and chlorambucil.
As with the previous two steps, the third step should be accom-
plished before the first definitive study occurs—that is, a historical
negative control database should be established for each species/
strain that will be used. One tip for efficiently developing historical
negative control databases is to collect and analyze pre-dosing
(i.e., “baseline”) blood samples, for example from rodents used in the
step 2 proficiency experiments, provided the methodology was con-
sistent with what will be used for future studies and sample
processing was technically proficient. Note that the ability to con-
struct historical negative control databases with naïve animals in com-
bination with those treated with common vehicles (e.g., sesame oil,
olive oil, water, 0.9% saline, phosphate buffered saline, and methylcel-
lulose/aqueous solutions) stems from the equivalence of their MUT
RET/RBC frequencies (OECD, 2020a).
The development of historical negative control databases also ben-
efits from the fact that while rat reticulocyte frequencies (i.e., %RET)
tend to be influenced by sex and age, no significant differences in nega-
tive control MUT RET/RBC frequencies have been detected between
rodents that differ in age by several months (OECD, 2020a). Thus, it is
possible to use a range of ages for building historical negative control
MUT RET/RBC databases provided this variable is tracked and periodi-
cally reconsidered for its influence on MUT RET/RBC frequencies.
Based on the literature, it should be acceptable to initially consider
sex as having no effect on negative control MUT RET/RBC frequencies
from young, healthy rodents (Labash et al., 2015). Thus, historical nega-
tive control distributions can initially be constructed using animals of
either sex, or both sexes combined. However, similar to the age vari-
able, laboratories should periodically reconsider the assumption that
sex has no influence on MUT RET/RBC frequencies by testing for an
effect using the data for males and females in the database. As long as
sex is not found to be a significant factor, the MUT RET/RBC distribu-
tions can be assembled by combining data from both male and female
animals. If sex differences are observed, this would indicate that sex-
specific historical negative control databases are appropriate for this
rodent model. Likewise, data collected from different rodent strains
should be tracked in a similar fashion and pooled only if there are no
statistical differences between the MUT RET/RBC data distributions.
When first acquiring data for inclusion in the historical negative con-
trol database, they should be consistent with published data (Shemansky
et al., 2019). As more experimental data are added to the historical con-
trol database, MUT RET/RBC frequencies from individual naïve and/or
vehicle control animals should be free from known technical error and
ideally fall below the upper bounds of the existing historical negative
control distribution (see below for exceptions). Various distribution
models are acceptable and should be internally justified prior to use.
Generally speaking, “observed range” (i.e., lowest to highest observed
frequencies) is not useful for describing the historical negative control
distribution except when the number of individual animals studied is very
low (e.g., n < 30). Once sufficient numbers of animals are included in the
database, other approaches for characterizing the historical negative con-
trol distribution are preferred, for example, 95% control limits, 99% con-
trol limits, prediction intervals, and tolerance intervals (Vardeman, 1992).
Prior to implementing a model for ascertaining distribution limits, one
should ensure a priori requisites such as normality are satisfied. Data
transformation(s) can be valuable for this purpose.
Note also that by definition, a small proportion of MUT RBC/RET fre-
quencies are expected to fall outside of an existing historical negative con-
trol distribution, and that all technically valid data should be included to
accurately represent negative control MUT RET/RBC frequencies. That
being said, given the clonal nature of mutation, an extreme high outlier can
be expected on rare occasions. For instance, the authors have observed
rare naïve mice and rats to have hundreds or even thousands of mutant
cells per million. In these cases, when an individual single animal's mutant
frequency markedly distorts historical negative control distribution metrics,
it will often be appropriate to omit the individual from the database.
The laboratory's historical negative control database should be
adequate for assessing the acceptability of negative control data in a
definitive study. Therefore, as a starting point, each laboratory should
acquire MUT RET/RBC frequency measurements from at least 30 naïve
and/or vehicle-treated animals from each rodent strain used for testing.
Each MUT RET/RBC frequency value should be acquired from an indi-
vidual animal. Thus, multiple serial blood samples from the same animal
should not be added to the historical negative control database. Finally,
the data should be acquired from at least three independent experi-
ments that each use progeny from different breeding cycles.
Figure 1 illustrates a set of historical negative control data (n = 39
male and female Crl:CD[SD] rats) derived from 13 separate studies
conducted over 14 months. As described in the original report
(Dertinger et al., 2019), these rats were exposed to one of several
common vehicles and were 7 weeks old at time of blood collection.
Restricted Maximum Likelihood (REML) analysis was conducted to
evaluate the degree to which sex, study number, and inter-animal dif-
ferences contributed to the variation in %RET and MUT RET/RBC fre-
quencies (Corbeil and Searle, 1976). As shown by Figure 1, variation
in %RET is dominated by sex (75%; males > females). On the other
hand, MUT RET/RBC variation is mainly attributable to inter-animal
variation (72–91%), with much lower contributions from sex (2–
8%) and study number (8–21%).
3 | EXPERIMENTAL DESIGN
3.1 | Animal considerations
The Pig-a assay has been performed most often with several com-
monly used laboratory strains of rat, including Sprague Dawley, Wistar
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Han, and Fischer 344 (Shemansky et al., 2019). Other rodent strains
or species (including, e.g., transgenic mice) may be used provided they
are responsive to known mutagenic agents, and historical negative
control databases have been established as described above. Rats
should be 4- to 10-weeks old when dosing begins. Animals outside of
this age range can be used, if appropriately justified. Animals are ran-
domly assigned to negative control and test substance dose groups
and should be uniquely identified after acclimatization to laboratory
conditions for at least 3 days (or as prescribed by the applicable
IACUC or their equivalent). Before randomized group assignment, it is
recommended that an individual rat's body weight does not exceed
±20% of the group mean weight (sexes considered separately), and if
a pre-dosing assay is conducted, acceptable Pig-a mutant cell frequen-
cies may be used as a requisite for placement on study (discussed
below).
The Pig-a assay can be performed in either sex; the majority of
published rodent Pig-a studies, however, have utilized only males. In
the case of single sex rat studies, at least six animals should be ran-
domly assigned to each treatment group (Dertinger et al., 2011a;
Gollapudi et al., 2015; OECD, 2020a). Whereas the goal is to have six
analyzable rats per treatment group at the end of the study, if for
unforeseen circumstances five animals remain in one or more treat-
ment groups, the study is still considered valid (Gollapudi et al., 2015).
Generally, at least four dose groups will be necessary: concurrent
vehicle control, and low, mid and high dose groups. If data are not
available to set appropriate dose levels, it is recommended first to per-
form a dose range finding study to select the maximum tolerated
dose, maximum feasible dose, or determine the appropriateness of
the regulatory limit dose (i.e., 1,000 mg/kg/day when dosing is con-
ducted for ≥14 consecutive days). As with other in vivo genotoxicity
studies, lower doses are generally separated by a factor of 2–3. If
lower dose levels are necessary, for instance when the Pig-a endpoint
is being integrated into a 28-day repeat-dose toxicology study that is
attempting to find a no observed adverse effect level or a benchmark
dose, it will often be preferable to add additional dose group(s) as
opposed to relying on very wide dose spacing.
If there are data indicating a difference in a test substance's toxic-
ity, metabolism, or bioavailability between males and females, both
sexes should be studied. Furthermore, it is also important to recognize
that initiatives are underway to increase the number of preclinical and
clinical studies that consider sex as a biological variable (NIH, 2015;
Miller et al., 2017). It is therefore conceivable that over time more
safety assessment studies will include both sexes. When both sexes
are studied, equal numbers should be used in each treatment group.
For studies that require different dose levels for males and females,
the number of animal/sex/group will be similar to the single sex stud-
ies: that is, at least six males and six females per group, with a target
of five per sex at the end of the study. For studies that treat animals
of both sexes with the same dose levels, it is possible to reduce the
number of animals per group. In these cases, it is useful to take advan-
tage of factorial statistical designs which help maintain statistical
power while limiting animal use. The requirement for proficiency dem-
onstrations as described above, coupled with 3Rs principles and the
desirability of integrating the Pig-a assay within other toxicity tests,
means that concurrent positive control animals are not ordinarily
required. However, when laboratories are gaining experience with the
Pig-a assay, or for other reason(s) desire concurrent positive control
rodents in their studies, it is not necessary to treat positive control
animals using the same route of exposure, same vehicle, same treat-
ment schedule, or on the same days that study animals are dosed. The
latter design consideration takes advantage of the persistence of ele-
vated MUT RET/RBC in circulation following exposure to mutagenic
substances. For instance, one efficient and effective scenario is to
expose positive control rats to ENU (e.g., 20 mg ENU/kg/day via oral
gavage) on study Days 1, 2, and 3. Blood can then be collected from
these animals much later, that is, at the same time blood samples from
study animals that were treated over the course of several weeks are
harvested (as described in more detail, below).
3.2 | Treatment and blood sampling schedule
A 28-day repeat-dose protocol is preferred for conducting the Pig-a
assay for regulatory safety assessments. Of the dosing schedules eval-
uated to date, the 28-day repeat-dose schedule offers the most com-
pelling evidence that a negative (non-mutagenic) test result is reliable
(OECD, 2020a; 2020b). Other repeat-dose protocols may also be
acceptable, if scientifically justified. There may also be instances when
an acute dosing regimen is preferable, for instance when certain other
genotoxicity endpoints are included in the experiment, and/or when
there is a desire to maximize the cumulative test substance dose or
plasma levels, albeit for a short time, as opposed to total exposure
over a more extended period of time (Roberts et al., 2016). Whenever
an acute treatment schedule is employed, it must be scientifically jus-
tified, and it is important to take the expression time of the MUT
RET/RBC into account, which generally means delaying blood sample
collection time(s) for two or more weeks.
Regardless of the dosing schedule, it will often be advantageous
to perform Pig-a analyses prior to the first administration of test sub-
stance (i.e., baseline samples taken within 1 week of dose initiation).
As indicated above, this facilitates removal of rare “jackpot” animals
from study that exhibit unusually high spontaneous MUT RET and/or
MUT RBC frequencies. The utility of baseline analyses was foreseen
by a renowned geneticist and mutagenesis expert who explained to
one of the authors (SDD) when rodent blood-based Pig-a assays were
beginning to be investigated: “You should be prepared to deal with
outliers from the beginning for it is in the nature of spontaneous
mutations to be clonal—non-mutants are also clonal, but are invisible
as clones” (Dr. John Heddle, Professor Emeritus, York University, July
4, 2008).
When animals are exposed to a test substance using the pre-
ferred treatment schedule, 28 consecutive days, at least one post-
exposure blood sample should be collected from each animal within
day(s) of exposure cessation (e.g., Days 29–31; where “Day 1” is the
day treatment begins). Data collected from testing diverse
genotoxicants suggest that this is sufficient time for adequate
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manifestation of MUT RET/RBC responses and that the exact timing
of sample collection within the suggested time window is not critical
(OECD, 2020a; 2020b). This schedule has the advantage of facilitating
integration of the Pig-a assay within commonly utilized general toxic-
ity and other genetic toxicology study designs. Accordingly, the test
substance may be administered via one of the standard rodent routes:
oral (gavage, diet, or drinking water), subcutaneous, inhalation, or
intravenous; non-standard routes can be used when scientifically jus-
tified. Note that an extra administration of test substance on Day
29, followed by sample collection several hours later, is permissible
for accommodating tissue harvest when integrating the in vivo comet
assay.
While additional time points are not required, there are certain
opportunities to conduct Pig-a analyses on blood samples collected at
later time points. For instance, some toxicology experiments include
“recovery” or “withdrawal” groups to evaluate whether toxic effects
diminish, resolve, or increase upon discontinuation of dose. Blood
samples from such animals are typically collected between 2 and
4 weeks after cessation of dosing and represent another opportunity
to evaluate MUT RET/RBC (and provides additional time for manifes-
tation of MUT RET/RBC induced by the doses administered later in
the study).
4 | BLOOD HARVEST, STORAGE, AND
TRANSPORTATION
Applying animal welfare standards that minimize discomfort and
stress, small volumes of peripheral blood can be obtained using a
method that permits survival of the animal, such as bleeding from the
tail vein, jugular vein, or other appropriate blood vessel. Alternately,
immediately after animals are sacrificed, blood can be collected via
cardiac puncture or sampling from a large blood vessel (abdominal
aorta or vena cava). As flow cytometric analysis requires single cell
suspensions, care must be taken to avoid blood coagulation. This is
normally accomplished using an anticoagulant, such as heparin and/or
EDTA. It is good practice to collect at least two-times more blood than
is necessary for the Pig-a assay. This represents a back-up that can be
useful for myriad reasons that include a labeling/technical issue that
compromises the mutant analysis, shipment failures (delayed/lost/
damaged during transit), or when a determination has been made that
more cells need to be analyzed.
In the presence of anticoagulant, blood samples can be stored for
up to 5 days before they are processed for flow cytometric analysis as
long as they are maintained cold, but not frozen (e.g., in a 4C refriger-
ator; Gollapudi et al., 2015). Furthermore, anticoagulant-treated blood
samples can be shipped to an analytical facility provided they are
maintained cold throughout transportation and any subsequent stor-
age, and as long as they are further processed/analyzed within 5 days
of collection (Gollapudi et al., 2015).
Procedures also have been described for freezing and later
thawing blood samples for subsequent processing and flow cytometric
analysis of Pig-a MUT RET/RBC frequencies (Avlasevich et al., 2019).
These procedures can be useful for delaying analysis for reasons that
include instrument failure, deferring the decision to acquire Pig-a data,
and storing blood from mutagen-treated animals for use as analytical
positive control samples. Furthermore, frozen blood samples can be
transported from an in-life site to an analytical site provided they are
maintained frozen throughout transportation (e.g., on dry ice)
(Avlasevich et al., 2019). Whatever freezing and thawing method is
employed, it is important to demonstrate minimal lysis of RBCs, and
that the freezing and thawing process, and length of storage, have
minimal impact on MUT RET/RBC and RET frequencies.
5 | SYSTEMIC EXPOSURE
A negative in vivo Pig-a test result will carry no weight unless evi-
dence is provided that the bone marrow was exposed to the test sub-
stance. With toxic compounds, evidence of bone marrow exposure
can be demonstrated by significant changes to the percentage of
reticulocytes in peripheral blood circulation. This will usually be seen
as reduction in %RET when blood is collected within hours to day(s)
of treatment cessation. However, when blood is collected several
days or more after discontinuing treatment, it can manifest as ele-
vated %RET frequencies due to stress erythropoiesis. (Note that
Nicolette et al., 2018 demonstrated that regenerative erythropoietic
response does not increase the frequency of MUT RET/RBC in rats.)
Test substance-induced hemolysis is another situation that can mani-
fest as elevated frequencies of reticulocytes and represents evidence
of systemic exposure (Kenyon et al., 2015). In the absence of toxicity
to the erythropoietic system, other evidence can be provided by con-
comitantly measuring plasma or blood levels of the test substance
and/or its metabolites, since bone marrow is extremely well-perfused
(Marenzana and Arnett, 2013; EFSA, 2017; Grüneboom et al., 2019).
ADME (absorption, distribution, metabolism, and excretion) data,
obtained in an independent (i.e., a separate) study using the same dos-
ing route and same species, may also be used to demonstrate bone
marrow exposure. Another way to ensure systemic exposure for
chemicals with in vitro genotoxic activity and low likelihood of
reaching the bone marrow due to chemical reactivity is to administer
the test substance intravenously. This was recently done to support a
negative Pig-a finding in an aryl boronic acid study (Masuda-Herrera
et al., 2019).
6 | DATA ACQUISITION
6.1 | Flow cytometry
Flow cytometric analysis is the analytical method of choice for deter-
mining circulating RET and MUT RET/RBC frequencies. The preferred
antibodies used to prepare erythrocytes for flow cytometric analysis
are anti-CD59 for rats and anti-CD24 for mice (Gollapudi et al., 2015;
OECD, 2020a). Other GPI-anchored proteins exist on the surface of
wild-type RBCs (e.g., CD55), and antibodies against such surface
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markers can be used if sufficiently validated. Additionally, it is possible
to use combinations of antibodies to distinguish wild-type from
mutant phenotype cells (e.g., anti-CD59 and anti-CD55). However, a
single antibody against the highly expressed CD59 and CD24 surface
markers are sufficient for assaying Pig-a mutant frequencies in rats
and mice, respectively.
When a positive control group is not included in a study, a
“mutant mimic” or comparable sample should be used to demonstrate
the light scatter and fluorescence characteristics of wild-type versus
MUT RET/RBC. Mutant mimics can be created by processing extra
blood from a vehicle control animal and omitting the fluorescent GPI-
anchored antibody(s) from the labeling protocol (Phonethepswath
et al., 2010; Raschke et al., 2016). Since mutant mimics are valuable
for guiding instrumentation settings and software/data analysis
parameters, they should be generated for every study, and used each
day blood samples are analyzed.
An alternative to mutant mimics is to use blood samples previ-
ously collected from mutagen-dosed (positive control) animals. Such
samples can be stored frozen (as described above) and used to iden-
tify the light scatter and fluorescence characteristics of wild-type ver-
sus MUT RET/RBC. In these cases, it is usually sufficient to include
1–3 such blood samples each day of analysis. When these samples are
being used in place of mutant mimics, the positive control blood
sample(s) should demonstrate levels of MUT RET/RBC that are ele-
vated sufficiently to establish the fluorescence characteristics of
mutant phenotype cells. For this purpose, it is ideal for the mutant fre-
quency in these two cell populations be at least 100 mutant cells per
million erythrocytes.
6.2 | Number of cells evaluated
According to industry best practices, as well as the IWGT Pig-a expert
report and Pig-a Detailed Review Paper, the minimum number of RBC
and RET that should be evaluated for the Pig-a mutant phenotype per
animal and per time point is 1 × 106 (Gollapudi et al., 2015;
OECD, 2020a). This was the minimum number of cells analyzed for
each of the chemicals included in the retrospective validation report
(OECD, 2020a; 2020b). Therefore, analyzing 1 × 106 RET and RBC for
Pig-a mutation has been shown to be effective at detecting mutagenic
test substances.
While 1 × 106 cells analyzed per animal and per time point has
been a widely cited minimum, it is important to keep analyses that
return zero (0 × 10−6) mutant cell frequency readings to an occasional,
rather than common, occurrence. Proficient laboratories have shown
that for commonly used rodent models, mean baseline MUT RET/RBC
frequencies are on the order of 1–3 × 10−6. Given this information, it
should not be surprising that it may be necessary to evaluate more
than 1 × 106 cells in order to avoid a high prevalence of zero MUT
RET/RBC frequency readings. This decision about number of cells
evaluated per animal per time point is ideally made as the laboratory
develops their historical negative control database. This represents
the best time to set the number of cells evaluated in a data-driven
manner and is greatly preferred to relying on the cited minimum value
of 1 × 106 cells and having to defend study results that exhibit a high
prevalence of zero readings.
Finally, given the rarity of RET in peripheral blood circulation, it is
not practical to evaluate ≥1 × 106 RET directly from blood samples. In
order to overcome this problem, immunomagnetic separation proce-
dures prior to flow cytometric analysis were developed to increase
the number of RET (and in some cases the number of RBC) interro-
gated for MUT RET/RBC measurements (Kimoto et al., 2011a;
Dertinger et al., 2011b; Chickura et al., 2021). These immunomagnetic
separation techniques, or a validated alternative, are a practical solu-
tion for evaluating adequate numbers of cells as described above.
7 | STATISTICAL CONSIDERATIONS
Statistical analysis of biological data can be an area of contention.
There is no single correct method of conducting a statistical analysis,
and statisticians can differ in their preferred methodology. Some of
these differences are fundamental and deeply philosophical such as
between Bayesians and Frequentists. There is considerable concern
by a large proportion of statisticians at the continuing use of p-values
and statistical significance in the interpretation of results. Increasingly,
there is a preference for estimates of the size of effects with confi-
dence intervals to be evaluated in preference to p-values. (Bayesians
have a different viewpoint on this as well). Linked to this is the greater
emphasis on a modeling approach to data analysis brought about in
part by the developments in statistical theory and the availability of
much greater computing power. This can create a clash between the
expectation for modern methods to be used against the use of
methods that are based upon approaches which were developed in
the pre-personal computer area and based upon algorithms and
methods which were, in effect, short-cuts or work arounds to the
analysis. It also can complicate the task of those seeking a simple
“yes/no” result from an experiment.
A practical approach is to suggest a particular set of statistical
analyses as an example of the sort of analyses that can be carried out.
It should be made clear that this is not a prescribed method and may
not be suitable for all sets of data. It would be quite acceptable for
someone to use an alternative method, especially if our suggested
method is not considered suitable. However, they must be prepared
to justify their approach.
7.1 | Data analyses
One set of statistical tests are pairwise comparisons of MUT RET/
RBC and RET frequencies in the concurrent vehicle control group with
those measured in the test substance exposed groups. Parametric
analyses such as ANOVA with post hoc multiple comparison tests are
commonly used, but other methodologies are equally acceptable.
Generally, these types of parametric tests should be performed only
when assumptions such as normality of the distribution within, and
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homogeneity of variance among groups are confirmed (e.g., using
tests such as, Levene's and/or Brown-Forsynthe tests). If
heteroscedasticity is identified, an appropriate data transformation
such as a logarithmic (log10) can be used. Note that if there are ani-
mals with 0 (zero) mutant frequency values, a small constant offset
value such as 0.1 should be added to every animal's mutant cell fre-
quency before transformation because log10 of zero is “not defined”
and will prevent calculations. If the transformation does not restore
homoscedasticity, non-parametric pairwise comparison methods may
be considered, for example the Kruskal-Wallis test and post hoc
Dunn's test. These methods can be extended to other experimental
designs, such as the factorial design, where both treatment and sex
are factors in the analysis.
A related statistical test described in current OECD in vivo gen-
otoxicity guidelines is a trend test to identify a dose–response
relationship. Care is needed in interpreting the results of some trend
tests, for instance a simple linear trend test, because they may fail to
detect a trend when, for instance, the dose–response is non-mono-
tonic. Trend tests capable of detecting non-monotonicity such as the
downturn protection test proposed by Bretz and Hothorn (2003), may
be useful in such cases.
The third analysis considers whether the mean MUT RET and/or
MUT RBC frequency of any test substance treatment group exceeds
the upper bounds of the historical negative control data distribution.
As discussed previously, there are several valid approaches for charac-
terizing the distribution of historical negative control data, including
prediction intervals, tolerance intervals, and control limits. In the field
of Quality Control, control limits are defined as lines plotted on a con-
trol chart 3 SDs above and below the mean. Each laboratory must
define an appropriate limit based on their data. In some instances, it
F IGURE 2 Mutant reticulocyte (MUT RET) and mutant erythrocyte (MUT RBC) frequencies are graphed for the same vehicle-exposed male
and female rats portrayed in Figure 1 (i.e., 78 individuals). In this case, the results are plotted on control charts according to the order that
analyses occurred (13 studies over 14 months). Zones A, B, and C signify values that are within 3, 2, and 1 SD from the mean, respectively. Nelson
rules violations (numbered 1–8) are superimposed on data points when alerts are triggered. In the current example, “1” indicates a value is greater
than 3 SDs from the mean, while “2” signifies that nine or more points in a row are on the same side of the mean. Overall, the low number of
violations gives one confidence that the mutant cell scoring process is “under control.” While these charts were produced using the JMP software
(v12.0.1), other packages such as Minitab can produce similar charts, as can packages in the R statistical programming language
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may be appropriate to use a different interval, for example the 95%
reference interval (mean ±1.96 SDs). Also note that comparing group
means to an upper bound limit value derived from an appropriate his-
torical negative control distribution is not the only comparison that
can be made. For instance, it could also be useful to consider the rela-
tionship of individual animal's mutant cell frequencies to the historical
negative control upper bound limit value when a single rodent is so
highly elevated that it is responsible for the elevated group mean.
7.2 | Interpretation of results
When assessing Pig-a results, the study must first be deemed valid. This
includes, in part, mean concurrent vehicle control treatment group MUT
RET/RBC frequencies that are below the upper limit of the negative his-
torical control distribution and are technically uncompromised. This also
includes some demonstration that the historical negative control data-
base is of sufficient quality to provide a reasonable assessment of those
responses that exceed its distribution bounds. One recommended
method for assessing the quality of the historical control database is the
use of control charts in conjunction with Nelson rules (Nelson, 1984;
see Figure 2). Other factors such as the number of animals evaluated
per group, instances of zeros in the dataset, and sample quality should
be consistent with the guidance given above.
When evaluating whether the test substance induced increases in
MUT RET/RBC frequencies, the analytical approaches described
above are regarded as key tools. Positive test substances will result in
the aforementioned three elements (significant pairwise comparison,
significant trend increase, test substance response greater than the
historical negative control distribution) aligning with each other. Nega-
tive test substances will produce data that are not consistent with any
of the three elements used for consideration. Scientific judgment will
be essential in those cases where they are not all in agreement. This
paradigm is reinforced by an expert OECD genotoxicity working
group that concluded “…data should be interpreted based both on
statistics and biological relevance” (OECD, 2016).
In certain instances, even after applying expert judgment, it will
not be possible to classify a response as positive or negative. In these
cases the response is equivocal and further testing may be required to
resolve the mutagenicity of the test substance. This is obviously not
as straight-forward as conducting statistical tests and referring to an
immutable rubric to make final judgments, but it is considered the best
scientific approach according to the aforementioned expert working
group (OECD, 2016).
8 | CLOSING THOUGHTS
The Pig-a assay represents an efficient means for studying the poten-
tial of chemicals to induce mutation in vivo in hematopoietic cells. The
need for systemic availability of the test substance, coupled with
knowledge about the kinetics by which MUT RET and MUT RBC
appear in peripheral blood circulation, are the main determinants for
good experimental design and interpretation. The other critical factor
is analytical proficiency, which when demonstrated as described, will
generate a useful negative historical control distribution that is invalu-
able for assessing assay acceptability and assay responses. We hope
the recommendations provided herein will be helpful to the genetic
toxicology safety assessment community.
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